The Evolving Paradigm in the Treatment of HER2 Positive Metastatic Breast Cancer

home / news-network / the-evolving-paradigm-in-the-treatment-of-her2-positive-metastatic-breast-cancer

Vijayakrishna Gadi, MD, PhD, provides an overview of recent advancements in the treatment of HER2+ metastatic breast cancer with special consideration for challenges in the management of patients with CNS metastases.

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

EP. 1: Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

July 1st 2022

Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

EP. 2: Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

July 1st 2022

An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.

Role of Multidisciplinary Team in the Management of Patients with HER2+ BC and CNS Metastases

EP. 3: Role of Multidisciplinary Team in the Management of Patients with HER2+ BC and CNS Metastases

July 8th 2022

Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.

Updates in the Treatment of HER2+ mBC from ASCO 2022

EP. 4: Updates in the Treatment of HER2+ mBC from ASCO 2022

July 8th 2022

A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.